Pulmonary Vascular remodelling in hypoxic rats: effects of amlodipine, alone and with perindopril

Jeffery, Tina K. and Wanstall, Janet C. (2001) Pulmonary Vascular remodelling in hypoxic rats: effects of amlodipine, alone and with perindopril. European Journal of Pharmacology, 416 1-2: 123-131. doi:10.1016/S0014-2999(01)00855-X

Author Jeffery, Tina K.
Wanstall, Janet C.
Title Pulmonary Vascular remodelling in hypoxic rats: effects of amlodipine, alone and with perindopril
Journal name European Journal of Pharmacology
ISSN 0014-2999: 879-0712
Publication date 2001-03-23
Sub-type Article (original research)
DOI 10.1016/S0014-2999(01)00855-X
Open Access Status Not yet assessed
Volume 416
Issue 1-2
Start page 123
End page 131
Total pages 9
Editor J. Bruinvels
D. de Wied
Place of publication Amsterdam, The Netherlands
Publisher Elsevier Science
Language eng
Subject 320502 Basic Pharmacology
730106 Cardiovascular system and diseases
Abstract This study investigated whether pulmonary Vascular remodelling in hypoxic pulmonary hypertensive rats (10% oxygen; 4 weeks) could be prevented by treatment, during hypoxia, with amlodipine (IO mg/kg/day, p.o.), either alone or in combination with the angiotensin converting enzyme inhibitor, perindopril (30 mg/kg/day, p.o.). Medial thickening of pulmonary arteries (30-500 mum o.d.) was attenuated by amlodipine whereas it was totally prevented by the combination treatment (amlodipine plus perindopril); neomuscularisation of small alveolar arteries (assessed from critical closing pressure in isolated perfused lungs) was not affected. Pulmonary vascular resistance (isolated perfused lungs) was reduced by both treatment regimes but only combination treatment reduced right ventricular hypertrophy. Taus, amlodipine has anti-remodelling properties in pulmonary hypertensive rats. The finding that combining amlodipine with another anti-remodelling drug produced effects on vascular structure that were additive raises the question of whether combination therapy with two different anti-remodelling drugs may be of value in the treatment of patients with hypoxic (and possibly other forms of) pulmonary hypertension. (C) 2001 Elsevier Science B.V. All rights reserved.
Keyword Pharmacology & Pharmacy
Pulmonary Hypertension
Pulmonary Vascular Remodelling
Ca2+ Channel Antagonist
Angiotensin Converting Enzyme Inhibitor
Smooth-muscle Cells
Angiotensin-converting Enzyme
Right-ventricular Hypertrophy
Hypertensive Rats
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Physical Sciences Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 13 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 14 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 01:07:20 EST